Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

Published:2019-12 Issue:12 Volume:20 Page:1681-1690
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ahn Myung-Ju,Han Ji-Youn,Lee Ki Hyeong,Kim Sang-We,Kim Dong-Wan,Lee Yun-Gyoo,Cho Eun Kyung,Kim Joo-Hang,Lee Gyeong-Won,Lee Jong-Seok,Min Young Joo,Kim Jin-Soo,Lee Sung Sook,Kim Hye Ryun,Hong Min Hee,Ahn Jin Seok,Sun Jong-Mu,Kim Heung Tae,Lee Dae Ho,Kim Sohee,Cho Byoung Chul

Publisher

Elsevier BV

Subject

Oncology

Reference14 articles.

1. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?;Girard;Future Oncol,2018

2. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway;Nguyen;Clin Lung Cancer,2009

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

4. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation;Odogwu;Oncologist,2018

5. YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival over osimertinib in animal model with brain metastases from NSCLC;Hong;J Thorac Oncol,2017

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

2. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA;Annals of Oncology;2024-09

3. Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?;Lung Cancer: Targets and Therapy;2024-07

4. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC;New England Journal of Medicine;2024-06-26

5. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control;Scientific Reports;2024-06-25